

## LETTER TO THE EDITOR

# Kidney immunology: embracing the complexity to advance the field

Leonardo V. Riella<sup>1</sup> and Paolo Cravedi<sup>2</sup>

<sup>1</sup>Center for Transplantation Sciences, Department of Surgery, Division of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA and <sup>2</sup>Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Correspondence and offprint requests to: Paolo Cravedi; E-mail: [paolo.cravedi@mssm.edu](mailto:paolo.cravedi@mssm.edu)

Abnormal immunity is involved in the pathophysiology of virtually any renal disease [1] and uremia *per se* has a significant impact on the immune system [2]. Nonetheless, the current understanding of specific immune abnormalities associated with different kidney diseases is quite rudimentary. This is responsible, at least in part, for the absence of specific treatments for most of these conditions.

Steroids, alkylating agents and calcineurin inhibitors have been the main treatments for most glomerular diseases, despite their different immune pathogenesis [3]. This simplistic treatment attitude was initially driven by the limited therapeutic options. However, the availability of biologics has offered numerous novel treatments that have not been integrated in the armamentarium of the nephrologists due to a lack of knowledge of the immune pathogenesis in individual glomerular diseases, including specific immune cells and molecular pathways that should be targeted.

A clear understanding of the pathophysiology of membranous nephropathy allowed testing the hypothesis that rituximab-induced B-cell depletion reduces disease severity by


arresting pathogenic autoantibody production [4]. It also resulted in a growing number of trials testing other biologics in this condition, which will likely translate into a further improvement in disease outcomes. Unfortunately, such success stories are uncommon in nephrology.

How can we do better? Immunology is not a major component of the nephrologists' curriculum and kidney diseases do not represent a key interest for immunologists. A strong commitment by the nephrology community is required to strengthen the immunological background of future generations of nephrologists through education and *ad hoc* funding opportunities.

In-depth human immunology research is essential to better understand kidney disease mechanisms, which will allow us to classify nephrological diseases based on pathophysiological principles instead of descriptive histological features. Immune nephrology (or 'kidney immunology') should become a key specialty of nephrology aimed at understanding the role of immunity in the pathophysiology of kidney diseases and at defining optimal immune modulating treatment strategies (Figure 1).

Received: 19.10.2021; Editorial decision: 8.11.2021

© The Author(s) 2021. Published by Oxford University Press on behalf of the ERA. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)



**FIGURE 1:** In-depth characterization of the human immune response in kidney disease. Human samples can be used for extensive profiling of immune, genetic and kidney abnormalities. The hypotheses generated from human studies can be tested in animal models and then in human mechanistic studies. Ultimately, these studies have the potential to identify new treatment targets and biomarkers that will improve the outcomes of affected individuals.

## FUNDING

L.V.R. is supported by the National Institutes of Health (NIH; grant R01 AI143887). This work was supported in part by the Assistant Secretary of Defense and Health Affairs through Reconstructive Transplant Research (awards W81XWH2010758 and W81XWH20110904, to L.V.R.). Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense. L.V.R. is supported in part by the Harold and Ellen Danser Endowed Chair in Transplantation at Massachusetts General Hospital (Boston, MA, USA). P.C. is supported by the NIH (grants R01 DK119431 and R01 AI132949).

## CONFLICT OF INTEREST STATEMENT

None declared.

## REFERENCES

1. Tecklenborg J, Clayton D, Siebert S *et al*. The role of the immune system in kidney disease. *Clin Exp Immunol* 2018; 192: 142–150
2. Betjes MGH. Uremia-associated immunological aging and severity of COVID-19 infection. *Front Med (Lausanne)* 2021; 8: 675573
3. Ponticelli C, Locatelli F. Glucocorticoids in the treatment of glomerular diseases: pitfalls and pearls. *Clin J Am Soc Nephrol* 2018; 13: 815–822
4. Faul C, Donnelly M, Merscher-Gomez S *et al*. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. *Nat Med* 2008; 14: 931–938